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Abstract
Background: Fleas are the most common ectoparasite infesting dogs globally. The many possible sequellae
of infestation include: direct discomfort; allergic reactions; and the transmission of pathogens. Rapid speed of
kill is an important characteristic for a parasiticide in order to alleviate the direct deleterious effects of fleas,
reduce the impact of allergic responses, and break the flea infestation cycle. In this study, the speed of kill of a
novel orally administered isoxazoline parasiticide, sarolaner (Simparica™) against fleas on dogs was evaluated
and compared with afoxolaner (NexGard®) for 5 weeks after a single oral dose.
Methods: Twenty-four dogs were randomly allocated to treatment with a single oral dose at label rate
of either sarolaner (2 to 4 mg/kg) or afoxolaner (2.5 to 6.8 mg/kg) or placebo, based on pretreatment
flea counts. Dogs were combed and live fleas counted at 8, 12 and 24 h after treatment and subsequent
re-infestations on Days 7, 14, 21, 28 and 35. Efficacy was determined at each time point relative to counts
for placebo dogs.
Results: There were no adverse reactions to treatment. A single oral dose of sarolaner provided ≥98.8 %
efficacy (based on geometric means) within 8 h of treatment or subsequent weekly re-infestations of fleas
to Day 35. By 12 h, fleas were virtually eradicated from all dogs, with only two fleas recovered from a single
sarolaner-treated dog on Day 7; efficacy was 100 % at all other time points. Significantly greater numbers
of live fleas were recovered from afoxolaner-treated dogs at 8 h on all days and at 12 h on Days 28 and 35
(P < 0.05).
Conclusions: In this controlled laboratory evaluation, sarolaner had a significantly faster speed of kill against
fleas than afoxolaner. This was noticeably more evident towards the end of the treatment period. The rapid
and consistent kill of fleas within 8 to 12 h after a single oral dose of sarolaner over 35 days indicates that this
treatment will provide highly effective control of flea infestations, relief for dogs afflicted with flea allergy
dermatitis, and should reduce the risk of flea-borne pathogen transmission.
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Background
Flea infestation of pets and the home are a common oc-
currence and their control and elimination can become
an expensive and time consuming challenge [1]. The cat
flea, Ctenocephalides felis felis, is the most abundant
ectoparasite of dogs and cats worldwide [2], and they
cause flea allergic dermatitis (FAD), serve as the vector of
various bacterial pathogens, and are the intermediate host
for filarid and cestode parasites. FAD has been recognized
as the most common dermatologic disease of dogs [3].
Ctenocephalides felis has been implicated in the transmis-
sion of Rickettsia typhi, Rickettsia felis, Bartonella hense-
lae, Mycoplasma haemofelis and, in rare cases, Yersinia
pestis [4–7]. Ctenocephalides felis also serves as the inter-
mediate host for the nonpathogenic subcutaneous filarid
nematode of dogs, Acanthocheilonema (Dipetalonema)
reconditum, as well as several species of cestodes includ-
ing Dipylidium caninum and Hymenoleptis spp. [1, 8, 9].
Effective control of fleas and their associated condi-
tions and diseases is dependent upon the rapid removal
of live fleas from the host. Fleas feed almost immediately
on attaining a host [10], and direct irritation and allergic
reactions are dependent upon the frequency and dur-
ation of feeding [11]. Similarly, the longer that a host is
exposed to feeding fleas the greater the chance of the
transmission of flea-borne pathogens. The use of highly
effective, topical and systemic parasiticides has allowed
the primary means of flea control to be via direct
treatment of the pet. These treatments have largely
eliminated the need to treat indoor and outdoor envi-
ronments, and their use as host targeted therapies
markedly reduces the severity and prevalence of FAD
[2]. Orally administered compounds, whether adminis-
tered daily like nitenpyram [12] or monthly like spino-
sad [13] have been introduced that provide rapid
systemic control of fleas for immediate daily treatment,
nitenpyram [12], or for up to a month following a sin-
gle dose, spinosad [13]. These applications have been
readily accepted by veterinarians and dog owners for
their efficacy, ease of use and the fact that these sys-
temic agents are not topically applied with the resultant
lower exposure of the owner or children to potentially
toxic residues. Recently, a new class of compounds, the
isoxazolines, have shown excellent efficacy against both
fleas and ticks for a month or longer following a single
orally administered dose [14, 15].
Sarolaner (Simparica™, Zoetis) is a new isoxazoline
effective against fleas and ticks for at least one month
following a single dose. A laboratory study was con-
ducted to compare the speed of kill of a single dose of
sarolaner (Simparica™, Zoetis) and afoxolaner (NexGard®,
Merial) against an existing flea (C. felis) infestation and




The study was a masked, negative controlled, randomized,
laboratory efficacy design conducted in the Republic of
South Africa. Procedures were in accordance with the
World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the effi-
cacy of parasiticides for the treatment, prevention and
control of flea and tick infestation on dogs and cats [16]
and complied with the principals of Good Clinical
Practices [17]. The protocol was reviewed and approved by
the local Institutional Animal Care and Use Committee.
Masking of the study was assured through the separation of
functions. All personnel conducting observations or animal
care or performing infestations and counts were masked to
treatment allocation.
Animals
Twenty-four, male and female, purpose-bred mongrel
dogs ranging in age from 15 to 105 months and weigh-
ing from 7.8 to 21.0 kg were used in the study. All dogs
had undergone an adequate wash-out period to ensure
that no residual ectoparasiticide efficacy remained from
any previously administered compound. Each dog was
individually identified by electronic transponder. The
dogs were acclimatized to study conditions for a mini-
mum of 14 days before treatment on Day 0. Dogs were in-
dividually housed in indoor runs such that no physical
contact was possible between dogs. Dogs were fed an ap-
propriate maintenance ration of a commercial dry canine
feed, and water was available ad libitum. All dogs were
given a physical examination to evaluate general health
and suitability for inclusion into the study. General health
observations were performed twice daily from the start of
the acclimation period to the end of the study.
Design
The study followed a randomized complete block design.
Dogs were ranked according to decreasing flea counts
into blocks of three and within each block a dog was
randomly allocated to treatment with placebo, sarolaner,
or afoxolaner. There were eight dogs per treatment
group. Dogs were infested with fleas prior to treatment
and then weekly following treatment for 5 weeks. Flea
counts were conducted at 8, 12 and 24 h after treatment
and each subsequent weekly re-infestation.
Treatment
Day -1 bodyweights were used to determine the appro-
priate dose to be administered. On Day 0, dogs received
either a placebo tablet, a sarolaner chewable tablet
(Simparica™) to deliver sarolaner at the minimum label
dose of 2 mg/kg (range 2 to 4 mg/kg), or NexGard® per
label directions (afoxolaner at 2.5 to 6.8 mg/kg). All
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doses were administered by hand pilling to ensure ac-
curate and complete dosing. Each dog was observed for
several minutes after dosing for evidence that the dose
was swallowed, and for general health at 1, 4 and 24 h
after treatment administration.
Flea infestation and assessment
The C. felis used in the study were from a locally main-
tained laboratory colony of European origin. The colony
was initiated in 2010 with fleas from Germany; fleas ob-
tained from Ireland were introduced into the colony in
2012. Flea infestations were performed on Days -7 (host
suitability and allocation), -1, 7, 14, 21, 28 and 35. At
each infestation a precounted aliquot of 100 (±5) adult,
unfed C. felis were directly applied to the animal which
was gently restrained for a few minutes to allow the fleas
to penetrate and disperse into the hair coat. Each dog
was examined and combed to remove and count fleas at
24 h after the initial host suitability infestation, and at 8
(±1), 12 (±1) and 24 (±2) hours after treatment and each
subsequent weekly re-infestation. Fleas were replaced on
the dogs immediately after each 8 and 12 h evaluation,
and discarded after the 24 h counts.
Flea counts were performed by personnel trained in the
standard procedures in use at the test facility. Commercial
fine-toothed flea combs were used. Dogs were combed
using repeated strokes initially while standing starting
from the head, then proceeding caudally along the dor-
sum. The dog was then placed on each side and then on
its back for combing of the sides and ventral surfaces.
After a few combing strokes were completed, the comb
was examined and hair and fleas were removed from the
comb and all live fleas were counted. Each animal was
examined for a minimum of 10 min; if any fleas were re-
covered in the last minute, combing was continued in
one-minute increments until no fleas were detected.
Statistical analysis
The individual dog was the experimental unit and the
primary endpoint was the live flea count. Data for post-
treatment flea counts were summarized with arithmetic
and geometric means by treatment group and timepoint.
Flea counts were transformed (loge(count + 1)) prior to
analysis in order to stabilize the variance and normalize
the data. Using the PROC MIXED procedure (SAS 9.2,
Cary NC), transformed counts were analyzed using a
mixed linear model. The fixed effects were treatment,
timepoint and the interaction between timepoint and
treatment by timepoint. The random effects included
room, block within room, block by treatment interaction
within room, and error. Testing was two-sided at the
significance level α = 0.05.
The assessment of efficacy was based on the percent
reduction in the arithmetic and geometric mean live
flea counts relative to placebo calculated using Abbott’s
formula:
% reduction ¼ 100  mean count placeboð Þ–mean count treatedð Þ
mean count placeboð Þ
Results
There were no treatment-related adverse events ob-
served during the study. Placebo-treated dogs main-
tained good flea infestations throughout the study and
these counts were maintained even following the comb-
ing and re-infestation procedures at 8 and 12 h (Tables 1,
2 and 3).
At the 8-h time point, both treatments resulted in sig-
nificantly lower flea counts than placebo-treated dogs
(P ≤ 0.0005) throughout the study (Table 1). Treatment
with sarolaner also resulted in significantly lower flea
counts than afoxolaner at 8 h on all assessment days
(P ≤ 0.0499) and the sarolaner treatment provided greater
and more consistent efficacy at 8 h (≥98.8 %, ≥97.9 % geo-
metric, arithmetic mean) for the entire study. Efficacy
based on geometric means for afoxolaner ranged from
76.3 to 99.4 %, and on arithmetic means from 65.2 to
99.1 % (Table 1). Notably, the efficacy for the afoxolaner-
treated dogs declined as the study progressed, and
was <90 % from Day 21 onwards (Fig. 1).
At the 12-h timepoint, both treatments resulted in sig-
nificantly lower flea counts than placebo-treated dogs
(P ≤ 0.0001) throughout the study (Table 2) and flea
counts were significantly higher for afoxolaner-treated
dogs on Days 28 and 35 (P ≤ 0.0161). Efficacy was very
high for sarolaner with only two live fleas found on one
dog on Day 7 (efficacy of 99.6 %); on all other days efficacy
for sarolaner was 100 %. For afoxolaner, 100 % efficacy
was only achieved on Day 0, and efficacy tended to decline
as the study progressed (Fig. 1). On Days 28 and 35, effi-
cacy for afoxolaner-treated dogs was <95 % (arithmetic
mean) (Table 2).
At the 24-h time point, both treatments resulted in
significantly lower flea counts than placebo-treated dogs
(P ≤ 0.0001) throughout the study (Table 3). Both prod-
ucts provided ≥99.8 % reduction in mean live flea counts
through Day 35 with 100 % efficacy at most evaluations
(Table 3); there was no difference between the counts
for the two products on any assessment day (P ≥ 0.5043).
Discussion
For any parasiticide product providing flea control, the
product’s initial speed of kill is important to provide the
pet with rapid relief from the existing infestation. The
residual speed of kill is critical to decrease the likelihood
of transmission of vector borne disease, ensure that any
newly acquired fleas are rapidly eliminated before they
can reproduce, and assist in the management of flea
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Table 2 Mean live flea counts and efficacy relative to placebo at 12 h after treatment and post treatment re-infestations for dogs
treated with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 40–95 33–79 60–89 48–88 56–85 62–95
A. mean 62.3 59.5 74.6 75.8 70.0 80.4
G. mean1 60.4a 57.0a 74.1a 74.7a 69.3a 79.8a
Sarolaner Range 0–0 0–2 0–0 0–0 0–0 0–0
A. mean 0.0 0.3 0.0 0.0 0.0 0.0
Efficacy (%) 100 99.6 100 100 100 100
G. mean1 0.0b 0.1b 0.0b 0.0b 0.0c 0.0c
Efficacy (%) 100 99.7 100 100 100 100
P-value vs.placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Afoxolaner Range 0–0 0–2 0–2 0–4 0–28 0–25
A. mean 0.0 0.3 0.3 0.9 5.5 4.3
Efficacy (%) 100 99.6 99.7 98.8 92.1 94.7
G. mean1 0.0b 0.1b 0.1b 0.5b 2.5b 1.4b
Efficacy (%) 100 99.7 99.8 99.4 96.4 98.2
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 1.000 1.000 0.2455 0.0713 0.0008 0.0161
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Table 1 Mean live flea counts and efficacy relative to placebo at 8 h after treatment and post treatment re-infestations for dogs
treated with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 44–99 51–91 69–89 55–92 62–97 75–100
A. mean 69.9 74.9 77.0 79.8 79.1 87.5
G. mean1 68.1a 73.3a 76.6a 78.8a 78.4a 87.1a
Sarolaner Range 0–0 0–3 0–0 0–0 0–8 0–5
A. mean 0.0 0.4 0.0 0.0 1.6 0.6
Efficacy (%) 100 99.5 100 100 97.9 99.3
G. mean1 0.0c 0.2c 0.0c 0.0c 1.0c 0.3c
Efficacy (%) 100 99.7 100 100 98.8 99.7
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Afoxolaner Range 0–2 0–35 0–31 0–44 3–66 0–71
A. mean 0.6 6.1 10.1 15.3 27.5 25.0
Efficacy (%) 99.1 91.8 86.9 80.9 65.2 71.4
G. mean1 0.4b 2.4 b 6.8b 8.5b 18.6b 11.3b
Efficacy (%) 99.4 96.7 91.1 89.2 76.3 87.0
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 0.0005 0.0005
P-value vs. sarolaner 0.0499 0.0094 <0.0001 <0.0001 <0.0001 <0.0001
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
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allergic dermatitis. The added benefit for products pre-
scribed by a veterinarian is instilling pet owner confidence
in the outcome of the treatment and the treatment recom-
mendation which can enhance compliance. A single oral
dose of sarolaner at the proposed commercial dose of 2 to
4 mg/kg resulted in the rapid reduction of an existing flea
infestation as well as rapid kill of newly infested fleas for
35 days. Treatment with sarolaner resulted in effective
control of greater than 97 % within 8 h after treatment
and weekly re-infestations for 35 days, and fleas were vir-
tually eliminated from all dogs within 12 h over the entire
35 days. This rapid efficacy will disrupt the flea life cycle
by killing adult fleas before they can lay eggs, thus redu-
cing the environmental infestation level [18, 19].
The efficacy provided by sarolaner at 8 h was signifi-
cantly greater than that provided by afoxolaner at all
Table 3 Mean live flea counts and efficacy relative to placebo at 24 h after treatment and post treatment re-infestations for dogs
treated with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 36–87 28–88 48–87 53–73 43–73 58–83
A. mean 56.5 59.3 64.3 66.3 59.8 71.4
G. mean1 54.6a 56.6a 62.7a 66.0a 59.0a 70.8a
Sarolaner Range 0–0 0–1 0–0 0–0 0–0 0–0
A. mean 0.0 0.1 0.0 0.0 0.0 0.0
Efficacy (%) 100 99.8 100 100 100 100
G. mean1 0.0b 0.1b 0.0b 0.0b 0.0b 0.0b
Efficacy (%) 100 99.8 100 100 100 100
P-value vs.placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Afoxolaner Range 0–0 0–0 0–0 0–0 0–0 0–0
A. mean 0.0 0.0 0.0 0.0 0.0 0.0
Efficacy (%) 100 100 100 100 100 100
G. mean1 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b
Efficacy (%) 100 100 100 100 100 100
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 1.000 0.5043 1.000 1.000 1.000 1.000
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 8 and 12 h after treatment and weekly post treatment re-infestations
of fleas for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
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evaluations but especially when performance is com-
pared towards the end of the monthly treatment period
when the efficacy of afoxolaner declined below 90 %
from Day 21 onwards. Efficacy of afoxolaner was im-
proved at 12 h and again sarolaner had consistently bet-
ter kill of fleas and there were significantly more live
fleas recovered from the afoxolaner-treated dogs on
Days 28 and 35; sarolaner was 100 % effective on these
days. There was no difference between sarolaner and
afoxolaner at the 24 h assessments. The results for afox-
olaner in this study are in agreement with those reported
by Hunter et al. [20] who reported 99.6 % efficacy at
12 h and 100 % efficacy at 24 h against an existing in-
festation and efficacy ranging from 89.7 to 99.5 % at
12 h and ≥99.9 % efficacy at 24 h for 35 days.
The rapid and consistent speed of kill of fleas over a
period of 35 days makes sarolaner an excellent option
for monthly flea control that will reduce the direct irrita-
tion caused by flea infestation, assist in the prevention of
FAD, and should reduce the risk of flea-borne diseases.
Conclusions
A single oral dose of sarolaner at 2 to 4 mg/kg resulted
in more rapid control of an existing flea infestation than
afoxolaner with >97 % efficacy within 8 h of both treat-
ment and subsequent re-infestations for 35 days. Fleas
were virtually eliminated from all dogs within 12 h. Effi-
cacy of sarolaner at 8 h was significantly superior to
afoxolaner on all days, and at 12 h on Days 28 and 35.
Afoxolaner’s efficacy at 12 h decreased towards the end
of the month long treatment interval. The rapid and
consistent speed of kill provided by sarolaner over the 5
weeks following a single dose can provide peace of mind
for veterinarians and pet owners that there will be no
gap in protection against fleas when sarolaner is dosed
monthly, will reduce the deleterious effects of flea infest-
ation and the clinical signs of flea allergy dermatitis, and
should reduce the risk of flea-borne pathogen
transmission.
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